Literature DB >> 6144318

Comparison of the absorption and metabolism of sulphasalazine and acrylic-coated 5-amino salicylic acid in normal subjects and patients with colitis.

M J Dew, P Ebden, N S Kidwai, G Lee, B K Evans, J Rhodes.   

Abstract

Serum levels of 5-amino salicylic acid ( 5ASA ) and acetyl 5ASA have been measured in volunteers after ingestion of sulphasalazine (6 g) and compared with levels after an equivalent dose of acrylic coated 5ASA (2.4 g). The serum levels of both 5ASA and acetyl 5ASA were similar after each preparation apart from an early peak of 5ASA following acrylic coated 5ASA . Serum and urinary levels for 5ASA and acetyl 5ASA have been measured in colitic patients following equivalent doses of sulphasalazine and acrylic coated 5ASA . Serum levels were similar; 25% of the calculated ingested 5ASA was excreted in the urine after sulphasalazine compared with 20% following acrylic coated 5ASA .

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6144318      PMCID: PMC1463387          DOI: 10.1111/j.1365-2125.1984.tb02375.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  4 in total

1.  Treatment of ulcerative colitis with oral 5-aminosalicyclic acid in patients unable to take sulphasalazine.

Authors:  M J Dew; A D Harries; B K Evans; J Rhodes
Journal:  Lancet       Date:  1983-10-01       Impact factor: 79.321

2.  Maintenance of remission in ulcerative colitis with oral preparation of 5-aminosalicylic acid.

Authors:  M J Dew; P Hughes; A D Harries; G Williams; B K Evans; J Rhodes
Journal:  Br Med J (Clin Res Ed)       Date:  1982-10-09

3.  HA-966 effects on striatal dopamine metabolism: implications for dopamine compartmentalization.

Authors:  H J Broxterman; C F van Valkenburg; E L Noach
Journal:  J Pharm Pharmacol       Date:  1980-01       Impact factor: 3.765

4.  An oral preparation to release drugs in the human colon.

Authors:  M J Dew; P J Hughes; M G Lee; B K Evans; J Rhodes
Journal:  Br J Clin Pharmacol       Date:  1982-09       Impact factor: 4.335

  4 in total
  11 in total

Review 1.  Drug therapy of ulcerative colitis.

Authors:  B Crotty; D P Jewell
Journal:  Br J Clin Pharmacol       Date:  1992-09       Impact factor: 4.335

2.  Drug management of ulcerative colitis.

Authors:  S Barrow; S H Rees
Journal:  BMJ       Date:  1992-10-03

Review 3.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

4.  Mesalazine associated nephrogenic diabetes insipidus presenting as weight loss.

Authors:  E A Masson; J M Rhodes
Journal:  Gut       Date:  1992-04       Impact factor: 23.059

5.  Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion.

Authors:  L Staerk Laursen; M Stokholm; K Bukhave; J Rask-Madsen; K Lauritsen
Journal:  Gut       Date:  1990-11       Impact factor: 23.059

Review 6.  Medical treatment of ulcerative colitis: scoring the advances.

Authors:  C J Hawkey; A B Hawthorne
Journal:  Gut       Date:  1988-10       Impact factor: 23.059

Review 7.  Comparative tolerability of treatments for inflammatory bowel disease.

Authors:  R B Stein; S B Hanauer
Journal:  Drug Saf       Date:  2000-11       Impact factor: 5.606

Review 8.  Inflammatory bowel disease.

Authors:  G M Van Rosendaal
Journal:  CMAJ       Date:  1989-07-15       Impact factor: 8.262

9.  Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract.

Authors:  B Myers; D N Evans; J Rhodes; B K Evans; B R Hughes; M G Lee; A Richens; D Richards
Journal:  Gut       Date:  1987-02       Impact factor: 23.059

10.  Effect of polymer coating on faecal recovery of ingested 5-amino salicylic acid in patients with ulcerative colitis.

Authors:  H A Mardini; D C Lindsay; C M Deighton; C O Record
Journal:  Gut       Date:  1987-09       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.